Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Kummar S, et al. Among authors: sullivan dm. Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14. Clin Cancer Res. 2015. PMID: 25589624 Free PMC article. Clinical Trial.
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Kummar S, et al. Invest New Drugs. 2016 Jun;34(3):355-63. doi: 10.1007/s10637-016-0335-x. Epub 2016 Mar 21. Invest New Drugs. 2016. PMID: 26996385 Free PMC article. Clinical Trial.
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S. Holkova B, et al. Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7. Clin Cancer Res. 2016. PMID: 26446942 Free PMC article. Clinical Trial.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Among authors: sullivan dm. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA 3rd, Lush R, Neuger A, Sullivan DM, Munster PN. Daud AI, et al. Among authors: sullivan dm. Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318485 Clinical Trial.
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. Lancet JE, et al. Among authors: sullivan dm. Clin Cancer Res. 2011 Mar 1;17(5):1140-6. doi: 10.1158/1078-0432.CCR-10-1878. Epub 2011 Jan 13. Clin Cancer Res. 2011. PMID: 21233404 Free PMC article. Clinical Trial.
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K, Komrokji R, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Sweet K, et al. Among authors: sullivan dm. Clin Cancer Res. 2020 Jan 1;26(1):54-60. doi: 10.1158/1078-0432.CCR-19-2169. Epub 2019 Oct 21. Clin Cancer Res. 2020. PMID: 31636097 Free PMC article. Clinical Trial.
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Holkova B, et al. Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23. Clin Cancer Res. 2014. PMID: 25248382 Free PMC article. Clinical Trial.
Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Fishman MN, et al. Among authors: sullivan dm. Clin Cancer Res. 2006 Jan 15;12(2):523-8. doi: 10.1158/1078-0432.CCR-05-0928. Clin Cancer Res. 2006. PMID: 16428495 Clinical Trial.
234 results